Zydus Lifesciences Share PriceZydus Lifesciences

-7.9 (-1.53%)
As on 06 June, 2023 | 08:30 BSE: 532321 NSE: ZYDUSLIFE

Zydus Lifesciences Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Zydus Lifesciences

Start SIP

Zydus Lifesciences Share Price

  • Over 1 Month -1.33%
  • Over 3 Month 7.85%
  • Over 6 Month 23.38%
  • Over 1 Year 40.45%

Zydus Lifesciences Key Statistics

P/E Ratio 26.3
PEG Ratio -0.5
Market Cap Cr 51,633
Price to Book Ratio 2.6
EPS 16.6
Dividend 0.5
Relative Strength Index 50.44
Money Flow Index 34.87
MACD Signal 0.74
Average True Range 11.41

Zydus Lifesciences Investment Rating

  • Master Rating:
  • Zydus Lifesciences has an operating revenue of Rs. 17,580.30 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 15% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 17% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 95 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Zydus Lifesciences Financials
IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 2,4372,0872,2171,9811,919
Operating Expenses Qtr Cr 1,8071,6281,7201,4371,562
Operating Profit Qtr Cr 773459679544458
Depreciation Qtr Cr 120122124123123
Interest Qtr Cr 8589644142
Tax Qtr Cr 124129149101100
Net Profit Qtr Cr 491256451332247

Zydus Lifesciences Technicals


Current Price
-7.9 (-1.53%)
  • Bullish Moving Average
  • ___
  • 10
  • Bearish Moving Average
  • ___
  • 6
  • 20 Day
  • ₹510.29
  • 50 Day
  • ₹502.79
  • 100 Day
  • ₹483.58
  • 200 Day
  • ₹457.76
  • 20 Day
  • ₹511.32
  • 50 Day
  • ₹506.7
  • 100 Day
  • ₹482.38
  • 200 Day
  • ₹442.76

Zydus Lifesciences Resistance and Support

First Resistance ₹521.44
Second Resistance ₹524.87
Third Resistance ₹528.89
RSI 50.44
MFI 34.87
MACD Single Line 0.74
MACD 0.56
First Resistance ₹513.99
Second Resistance ₹509.97
Third Resistance ₹506.54

Zydus Lifesciences Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,064,864 51,763,039 48.61
Week 1,006,957 54,234,704 53.86
1 Month 1,124,272 51,536,644 45.84
6 Month 1,030,676 47,318,349 45.91

Zydus Lifesciences Result Highlights

Zydus Lifesciences Synopsis

NSE-Medical-Generic Drugs

Zydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 8731.60 Cr. and Equity Capital is Rs. 101.20 Cr. for the Year ended 31/03/2023. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.
Market Cap 51,633
Sales 9,046
Shares in Float 25.31
No of funds 258
Yield 1.16
Book Value 3.78
U/D Vol ratio 1
LTDebt / Equity 28
Alpha 0.13
Beta 0.59

Zydus Lifesciences

Owner NameMar-23Dec-22Sep-22Jun-22
Promoters 74.98%74.98%74.98%74.88%
Mutual Funds 5.59%5.56%5.36%4.62%
Insurance Companies 7.67%7.87%7.3%7.3%
Foreign Portfolio Investors 3.42%2.52%2.61%2.86%
Financial Institutions/ Banks 0.01%
Individual Investors 6.42%7.04%7.6%8.02%
Others 1.92%2.03%2.14%2.32%

Zydus Lifesciences Management

Name Designation
Mr. Pankaj R Patel Chairman
Dr. Sharvil P Patel Managing Director
Mr. Ganesh N Nayak Executive Director
Mr. Bhadresh K Shah Independent Director
Mr. Mukesh M Patel Non Executive Director
Mr. Nitin R Desai Independent Director
Ms. Dharmishtaben N Raval Independent Woman Director
Ms. Apurva S Diwanji Independent Director
Mr. Upasana Konidela Ind. Non-Executive Director
Mr. Monappa Arun Akhil Ind. Non-Executive Director

Zydus Lifesciences Forecast

Price Estimates


Other Analyst Rating

Zydus Lifesciences Corporate Action

Date Purpose Remarks
2023-05-18 Audited Results & Final Dividend
2023-02-03 Quarterly Results
2022-11-11 Quarterly Results
2022-08-10 Quarterly Results
2022-05-20 Audited Results, Dividend & Buy Back
Date Purpose Remarks
2023-07-28 FINAL Rs.6.00 per share(600%)Final Dividend
2022-07-29 FINAL Rs.2.50 per share(250%)Final Dividend

Zydus Lifesciences MF Shareholding

Name Amount(cr)
Kotak Flexicap Fund Growth 37217
Parag Parikh Flexi Cap Regular Growth 33616
Kotak Emerging Equity Scheme Growth 25972
Kotak Equity Arbitrage Fund Growth 20587
Nippon India Multi Cap Fund - Growth 15088

About Company

Zydus Lifesciences Limited (Zydus) is one of India’s leading pharmaceutical companies, engaged in the formulation and marketing of pharmaceutical products. Zydus Group has a leadership position in several segments in its portfolio with brands that are market leaders in their respective categories. 

The Group has a strong presence across therapeutic segments including pain management, cardiovascular diseases, urology and anti-infectives. It also offers over-the-counter healthcare products. It sells medicines through retail pharmacies, hospitals, and clinics to customers all over India and exports to various countries worldwide. 

The Company is organized into three business verticals: Pharmaceuticals, Active Ingredients and Contract Manufacturing Services (CMS). It manufactures active ingredients for use in formulations manufactured by other pharmaceutical companies; distributes finished formulations; provides contract manufacturing services for branded drugs, and markets finished formulations under its brand names.

Business Verticals

Zydus Lifesciences has three business divisions. The largest division is pharmaceuticals, which includes oral solid dosage and injectables. The second division is hospital equipment and supplies. Finally, there is a medical education division that includes training programs for medical professionals in both rural and urban areas as well as retail stores selling over-the-counter products to consumers.  

In addition to these divisions, Zydus Lifesciences provides consulting services for companies looking to enter or expand their presence in India. These services include regulatory and market access assistance, drug registration services, strategic marketing support and distribution channel optimization.



1995 - Cadila Healthcare Ltd, the flagship company of the Zydus Cadila Group, was founded.

1996 - It went public in July. They also formed a strategic alliance with Gulin Pharma of China and launched Falcigo, an anti-malarial segment, in India.

2000 - In May, the company acquired Recon Ltd's formulation business, to strengthen its position in the southern market.

2001 - Acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector at the time. The same year they formed a joint venture with US-based Onconova for collaborative research in the field of Oncogenomics.

2002 - In April, the company acquired Banyan Chemicals, a Vadodara-based company registered with the US Food and Drug Administration.

2003 - Zydus Group decided to merge German Remedies Ltd and Recon Healthcare Ltd with Cadila Healthcare Ltd

2004 - In November, the company formed a strategic alliance with the Zambon Group in Italy to explore new opportunities in contract manufacturing. The same year, the company signed a long-term strategic agreement with Boehringer Ingelheim India Ltd, a wholly-owned subsidiary of Boehringer Ingelheim (BI), to manufacture and market BI's products in India.

2005 - The company formed a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a Tyco Healthcare business unit, to market the company's product under a joint label. In the same year, the company formed a 50:50 joint venture with Australia's Mayne Pharma to produce generic injectable cytotoxic (anti-cancer) medicines as well as active pharmaceutical ingredients (API) for global markets.

2005-06 - During this fiscal year, the company formed a 50:50 joint venture with one of India's leading biotech companies, Bharat Serums and Vaccines Ltd (BSV), to develop, manufacture, and market a non-infringing and proprietary Novel Drug Delivery System (NDDS) of an approved anticancer product for global markets.

2006-07 - During this fiscal year, the company entered into a share purchase agreement to acquire a 97.95 per cent stake in Liva Healthcare Ltd, which manufactures and markets Formulations. They also built a brand-new green field facility for Solid Oral Dosage. They also built a Lyophilisation facility at the Moraiya plant with an annual capacity of 7.5 million dosages to serve both the Indian and international markets.

2007-08 - During this fiscal year, the company restructured its formulation division, Alidac, and launched two new subdivisions, Corza and Fortiza.

Zydus Lifesciences FAQs

What is Share Price of Zydus Lifesciences ?

Zydus Lifesciences share price is ₹510 As on 06 June, 2023 | 08:16

What is the Market Cap of Zydus Lifesciences ?

The Market Cap of Zydus Lifesciences is ₹51632.5 Cr As on 06 June, 2023 | 08:16

What is the P/E ratio of Zydus Lifesciences ?

The P/E ratio of Zydus Lifesciences is 26.3 As on 06 June, 2023 | 08:16

What is the PB ratio of Zydus Lifesciences ?

The PB ratio of Zydus Lifesciences is 2.6 As on 06 June, 2023 | 08:16

What were the company's most recent reported sales and net income?

Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20  crores in FY22

What is the future of the company's shares?

Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.

How to buy shares of Zydus Lifesciences Ltd.?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.


Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number